



(72) BROWN, DENNIS T., US

(72) HERNANDEZ, RACQUEL, US

(71) RESEARCH DEVELOPMENT FOUNDATION, US

(51) Int.Cl.⁷ C12N 7/00, C12N 15/86, A61K 39/12, C12P 21/00

(30) 1997/09/18 (60/059,668) US

(54) **MUTATIONS DE PLAGE HOTE DE VIRUS ENVELOPPE D'UNE
MEMBRANE ET LEUR UTILISATION COMME SUBSTRATS
DE VACCINS**

(54) **MEMBRANE VIRUS HOST RANGE MUTATIONS AND THEIR
USES AS VACCINE SUBSTRATES**

(57) La présente invention concerne des vaccins et des procédés basés sur des mutations de délétion dans des domaines de protéine transmembranaire de virus enveloppés d'une membrane. La stratégie de production de ces mutations est basée sur le fait qu'à la différence des membranes cellulaires de mammifère, les membranes cellulaires d'insecte ne contiennent pas de cholestérol et sont plus minces. Beaucoup de virus revêtus de membrane présentent des glycoprotéines membranaires sur leur surface qui permettent d'identifier et d'infecter des cellules de cible. Ces glycoprotéines membranaires présentent des domaines hydrophobes recouvrant une membrane, lesquels domaines ancrent les protéines dans la membrane formée de deux couches. Les domaines recouvrant la membrane de ces protéines transmembranaires doivent être assez longs pour passer d'un côté de la membrane formée de deux couches à l'autre côté de façon à maintenir les protéines dans cette membrane. La présente invention concerne également un vaccin, un procédé de fabrication de ce vaccin, et un procédé d'utilisation de ce vaccin, basé sur les différences entre les membranes des virus reproduits chez les invertébrés et les membranes des virus reproduits chez les vertébrés.

(57) The vaccines and methods of the present invention are based on deletion mutations in the protein transmembrane domains of membrane-enveloped viruses. The strategy for production of these mutations is based on the fact that unlike mammalian cell membranes, the membranes of insect cells contain no cholesterol; thus are thinner than mammalian membranes. Many membrane-coated viruses have membrane glycoproteins on their surface which are responsible for identifying and infecting target cells. These membrane glycoproteins have hydrophobic membrane-spanning domains which anchor the proteins in the membrane bilayer. The membrane-spanning domains of these transmembrane proteins must be long enough to reach from one side of the bilayer to the other in order to hold the proteins in the membrane. Provided is a vaccine, a method of producing this vaccine, and a method of using this vaccine, based on the differences between membranes of viruses replicated in invertebrates and membranes of viruses replicated in vertebrates.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K	A2	(11) International Publication Number: WO 99/13818 (43) International Publication Date: 25 March 1999 (25.03.99)
(21) International Application Number: PCT/US98/19556 (22) International Filing Date: 18 September 1998 (18.09.98) (30) Priority Data: 60/059,668 18 September 1997 (18.09.97) US (71) Applicant: RESEARCH DEVELOPMENT FOUNDATION [US/US]; 402 North Division Street, Carson City, NV 89703 (US). (72) Inventors: BROWN, Dennis, T.; 3126 Eton Road, Raleigh, NC 27695 (US). HERNANDEZ, Racquel; 3126 Eton Road, Raleigh, NC 27695 (US). (74) Agent: WEILER, James, F.; Suite 1560, 1 Riverway, Houston, TX 77056 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: MEMBRANE VIRUS HOST RANGE MUTATIONS AND THEIR USES AS VACCINE SUBSTRATES (57) Abstract The vaccines and methods of the present invention are based on deletion mutations in the protein transmembrane domains of membrane-enveloped viruses. The strategy for production of these mutations is based on the fact that unlike mammalian cell membranes, the membranes of insect cells contain no cholesterol; thus are thinner than mammalian membranes. Many membrane-coated viruses have membrane glycoproteins on their surface which are responsible for identifying and infecting target cells. These membrane glycoproteins have hydrophobic membrane-spanning domains which anchor the proteins in the membrane bilayer. The membrane-spanning domains of these transmembrane proteins must be long enough to reach from one side of the bilayer to the other in order to hold the proteins in the membrane. Provided is a vaccine, a method of producing this vaccine, and a method of using this vaccine, based on the differences between membranes of viruses replicated in invertebrates and membranes of viruses replicated in vertebrates.		

5

10 **MEMBRANE VIRUS HOST RANGE MUTATIONS AND
 THEIR USES AS VACCINE SUBSTRATES**

15 **BACKGROUND OF THE INVENTION**

Field of the Invention

 The present invention relates generally to virology and
disease control. Specifically, the present invention relates to
20 mutated arthropod vectored viruses and their uses as vaccines.

Description of the Related Art

 Arthropod vectored viruses (Arboviruses) are viral
agents which are transmitted in nature by blood sucking insects.
Many of these viruses have membrane bilayers with associated
25 integral membrane proteins which make up the protective

envelope of the virus particle (Togaviruses) (Schlesinger, S. and M.J. Schlesinger, 1990).

Collectively, the arthropod vectored viruses are second only to malaria as a source of insect-transmitted disease and death in man and animals throughout the world (Berge A. O. 1975). Among these viral agents are Eastern, Western, and Venezuelan Equine Encephalitis Viruses, Dengue Fever, Japanese Encephalitis, San Angelo Fever, and Yellow Fever. Further, diseases caused by these agents are in resurgence in North America (*NIAID Report of the Task Force on Microbiology and Infectious Diseases* 1992, NIH Publication No. 92-3320) as a result of the introduction of the mosquito vector *Aedes albopictus* (Sprenger, and Wuithiranyagool 1985).

By their very nature, Arboviruses must be able to replicate in the tissues of both the invertebrate insect and the mammalian host (Brown, D.T., and L. Condreay, 1986, Bowers et al. 1995). Differences in the genetic and biochemical environment of these two host cell systems provide a basis for the production of viruses which can replicate in one host but not the other (Host Range Mutants).

Currently, Dengue Fever and Eastern Equine Encephalitis and other insect bourn viruses are in resurgence in the United States. The U.S. Army and other government agencies have been trying to make vaccines against these viruses since the 1960s with little success. Thus, the prior art is deficient in a vaccine against most arthropod vectored viruses and other membrane-coated viruses. The present invention fulfills this long-standing need and desire in the art.

SUMMARY OF THE INVENTION

One object of the present invention is to provide a genetically-engineered, membrane-enveloped virus, wherein the virus codes for a transmembrane protein which has a deletion of one or more amino acids such that the transmembrane protein is able to span the viral membrane when the engineered virus replicates in insect cells, but is unable to span the viral membrane when the virus replicates in mammalian cells. One embodiment of this object of the invention provides an Arthropod vectoral virus as the genetically-engineered, membrane-enveloped virus. Further, in preferred embodiments, the Arthropod vectoral virus may be selected from the group of Togaviruses, Flaviviruses and Bunya viruses and all other enveloped viruses which can replicate naturally in both mammalian and insect cells, as well as enveloped viruses which can be made to replicate in mammalian and insect cells by genetic engineering of either the virus or the cell.

In another embodiment of the present invention, there is provided a method of producing a viral vaccine from a genetically-engineered, membrane-bound virus for vaccination of mammals, comprising the steps of: engineering an amino acid deletion in a viral transmembrane protein to produce an engineered virus, wherein the transmembrane protein is able to span the membrane envelope when the engineered virus replicates in insect cells, but is unable to span the membrane envelope when the virus replicates in mammalian cells, and wherein the virus remains capable of replicating in insect cells; introducing the mutated virus into insect cells; and allowing the

WO 99/13818

PCT/US98/19556

mutated virus to replicate in the insect cells to produce a viral vaccine.

In yet another embodiment of the present invention, there is provided a method for vaccination of an individual comprising the steps of: introducing the viral vaccine of the present invention into mammalian cells resulting in the non-productive infection of cells and tissues for immune surveillance.

Finally, the present invention also has the objective of providing a method of producing a viral vaccine from a genetically-engineered, membrane-bound virus to diseases spread by a wild mosquito population to mammals, comprising the steps of: engineering an amino acid deletion in a viral transmembrane protein to produce an engineered virus, wherein the transmembrane protein is able to span the membrane envelope when the engineered virus replicates in mosquito cells, but is unable to span the membrane envelope when the virus replicates in mammalian cells, and wherein the virus remains capable of replicating in wild mosquito cells; introducing the mutated virus into the wild mosquito population; and allowing the mutated virus to replicate in cells of the wild mosquito population to produce a population of mosquitos which harbor the vaccine strain of the virus and exclude the wild type (pathogenic) virus such that the mosquito bite delivers the vaccine to a mammal bitten.

Other and further aspects, features, and advantages of the present invention will be apparent from the following description of one of the presently preferred embodiments of the invention. These embodiments are given for the purpose of disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

The appended drawings have been included herein so that the above-recited features, advantages and objects of the invention will become clear and can be understood in detail. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and should not be considered to limit the scope of the invention.

Figure 1 shows the results of radiolabeled Sindbis virus proteins recovered from transfected tissue-cultured cells. BHK-21 cells mock transfected (1), transfected with mutant $\Delta 391$ RNA (2), and *Aedes albopictus* cells transfected with $\Delta 391$ RNA (3), were labeled with radioactive amino acids as described in Example 3. At 24 hours post-transfection, proteins were precipitated with virus specific anti-serum as described in Example 4. The figure shows that both BHK-21 cells and *Aedes albopictus* cells transfected with RNA of the deletion mutant produce the three viral structural proteins E1, E2, and C which are not detected in the mock transfected cells.

Figures 2a and 2b are electron micrographs of BHK-21 cells (2a) and *Aedes albopictus* cells (2b) transfected with RNA of the Sindbis virus deletion mutant $\Delta 391$. Cells were transfected as described in Example 2. BHK-21 cells (a) show clusters of virus core structures in the cell cytoplasm (A) even though these cells produce no mature virus (Table 1). *Aedes albopictus* cells (b) also produce clusters of virus cores; however, these cores are found free in the cells' cytoplasm similar to those in BHK-21 cells (A) and

WO 99/13818

PCT/US98/19556

are also found associated with cell membranes (B). This latter case is not found in BHK-21 cells, indicating that the glycoproteins E1 and E2, although present, do not function to bind them.

Figure 3 shows the configuration of Sindbis virus glycoproteins after integration into the ER. The protein is a multipass protein with 6 membrane spanning domains (numbered 1-6). 1. The signal sequence for initial integration. 2. The first E2 trans membrane domain (TMD)). 3. The second E2 TMD. 4. The first 6k TMD. 5. The second 6k TMD. 6. The E1 TMD. S = point of cleavage by signal peptidase.

Figure 4 shows the deleted amino acids in the E₂ transmembranal domain. The deleted sequence is shown under the appropriate amino acid, ranging from 1 deletion to 16. Histidine and Proline sequences beginning at nt. 9787 are on the luminal side of the protein but are used to design the mutagenic primers.

DETAILED DESCRIPTION OF THE INVENTION

It will be apparent to one skilled in the art that various substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

As used herein, the term "membrane-bound virus" refers to a virus which contains a lipid membrane bilayer as part of its protective exterior coat.

WO 99/13818

PCT/US98/19556

As used herein the term "viral envelope" refers to the lipid membrane component of the membrane containing virus and its associated proteins.

As used herein, the terms "arthropod vectored virus" or "Arbovirus" refer to viral agents which replicate and produce progeny virus in arthropod (insect) or mammalian cells. This includes Togaviruses, Flaviviruses and Bunyaviruses.

As used herein, the term "Togavirus" refers to a general classification of membrane containing viruses which include the Alphaviruses.

As used herein, the term "membrane bilayer" refers to a structure consisting of opposed amphipathic phospholipids. The bilayer is organized in cross section from polar head groups to non-polar carbon chains to nonpolar carbon chains to polar head groups.

As used herein, the term "glycoprotein transmembrane region" refers to the amino acid sequence of the region of a membrane-integrated protein which spans the membrane bilayer.

As used herein, the term "viral vaccine" refers to a strain of virus or virus mutant which has the antigenic properties of the virus but cannot produce disease.

As used herein the term "immune surveillance" refers to a process by which blood lymphocytes survey the cells and tissues of a mammal to determine the presence of foreign (virus) proteins and stimulates the production of lymphocytes capable of targeting cells producing the foreign protein for destruction. This

WO 99/13818

PCT/US98/19556

process also leads to the production of circulating antibodies against the foreign protein.

As used herein, the term "infectious virus particles" refers to viruses which are capable of entering a cell and
5 producing virus protein, whether or not they are capable of producing progeny virus.

As used herein, the term "non-infectious virus particles" refers to viruses which are not capable of infecting or entering a cell.

10 As used herein, the term "vertebrate cells" refers to any mammalian cell.

As used herein, the term "invertebrate cells" refers to any insect cell.

The present invention is directed to a genetically-
15 engineered, membrane-enveloped virus, wherein the virus codes for a transmembrane protein which has a deletion of one or more amino acids in the transmembrane protein such that the transmembrane protein is able to span the viral membrane when the engineered virus replicates in insect cells, but is unable to
20 span the viral membrane when the virus replicates in mammalian cells. One embodiment of this object of the invention provides an Arthropod vectoral virus selected from the group of Togaviruses, Flaviviruses and Bunya viruses and all other enveloped viruses which can replicate naturally in both mammalian and insect cells,
25 as well as enveloped viruses which can be made to replicate in mammalian and insect cells by genetic engineering of either the virus or the cell.

WO 99/13818

PCT/US98/19556

The present invention is drawn also to a method of producing a viral vaccine from a genetically-engineered, membrane-bound virus for vaccination of mammals, comprising the steps of: engineering an amino acid deletion in a viral transmembrane protein to produce an engineered virus, wherein the transmembrane protein is able to span the membrane envelope when the engineered virus replicates in insect cells, but is unable to span the membrane envelope when the virus replicates in mammalian cells, and wherein the virus remains capable of replicating in insect cells; introducing the mutated virus into insect cells, resulting in the production of mutated virus which can serve as a vaccine.

In addition, the present invention provides a method for vaccination of an individual, comprising the steps of: introducing the viral vaccine of the present invention into cells of an individual; and allowing the vaccine to produce viral proteins for immune surveillance in the individual.

Further, the present invention provides a method of producing a viral vaccine to diseases spread by a wild mosquito population, comprising the steps of: genetically engineering an amino acid deletion in a viral transmembrane protein to produce an engineered virus, wherein said transmembrane protein is able to span said membrane envelope when said engineered virus replicates in mosquito cells, but is unable to span said membrane envelope when said virus replicates in mammalian cells, and wherein the virus remains capable of replicating in mosquito cells; introducing the mutated virus into the wild mosquito population; and allowing the mutated virus to replicate in cells of the wild mosquito population to produce a population of mosquitos which

WO 99/13818

PCT/US98/19556

harbor the vaccine strain of the virus and exclude the wild type (pathogenic) virus such that the mosquito bite delivers the vaccine to a mammal bitten.

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Maniatis, Fritsch & Sambrook, "Molecular Cloning: A Laboratory Manual (1982); "DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover ed. 1985); "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid Hybridization" (B.D. Hames & S.J. Higgins eds. (1985)); "Transcription and Translation" (B.D. Hames & S.J. Higgins eds. (1984)); "Animal Cell Culture" (R.I. Freshney, ed. (1986)); "Immobilized Cells And Enzymes" (IRL Press, (1986)); B. Perbal, "A Practical Guide To Molecular Cloning" (1984).

Therefore, if appearing herein, the following terms shall have the definitions set out below.

A "vector" is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment. A vector is said to be "pharmacologically acceptable" if its administration can be tolerated by a recipient animal. Such an agent is said to be administered in a "therapeutically effective amount" if the amount administered is physiologically significant. An agent is physiologically significant if its presence results in a change in the physiology of a recipient mammal. For example, in the treatment of viral infection, a compound which decreases the extent of infection or of physiologic damage due to infection, would be considered therapeutically effective.

A "DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in either single stranded form, or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA).

A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. A polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For

purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at
5 levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always,
10 contain "TATA" boxes and "CAT" boxes. Various promoters may be used to drive vectors.

The term "oligonucleotide" or "probe" as used herein, refers to a molecule comprised of ribonucleotides or deoxyribonucleotides. The exact size of the oligonucleotide or
15 probe will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide. The length of the probe is not critical, but will usually comprise at least about 12 bases, more usually comprising at least about 16 bases, and the probe is substantially complementary to a portion of the bacterial
20 genome; however, the probe need not have perfect complementarity with the genome. The probes may be prepared synthetically, with suitable synthetic techniques, and most likely include a detectable label. Usually, the synthetic sequences are expanded in common, publicly-available cloning vectors and
25 suitable hosts in order to obtain large quantities of the probe. The expanded vectors may themselves be labeled for use as probes, or shorter fragments containing complementary strands may be excised and labeled. Methods for the preparation and utilization of nucleotide probes for diagnostic testing are described in the

references listed above, *supra*, and in U.S. Patent No. 4,358,535 to Falkow, et al.

The term "primer" as used herein refers to an oligonucleotide, whether occurring naturally as in a purified
5 restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, i.e., in the presence of nucleotides and an inducing agent such as a DNA
10 polymerase and at a suitable temperature and pH. The primer may be either single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature,
15 the source of primer and the method used. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 15-25 or more nucleotides, although it may contain fewer nucleotides.

The primers herein are selected to be "substantially"
20 complementary to different strands of a particular target DNA sequence. This means that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template. For example, a non-complementary
25 nucleotide fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being complementary to the strand. Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the

WO 99/13818

PCT/US98/19556

sequence or hybridize therewith and thereby form the template for the synthesis of the extension product.

As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence.

A cell has been "transfected" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. The transfecting DNA may or may not be integrated (covalently linked) into the genome of the cell. A "clone" is a population of cells derived from a single cell or common ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth in vitro for many generations.

A "heterologous" region of the DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. In another example, coding sequence is a construct where the coding sequence itself is not found in nature (e.g., a cDNA where the genomic coding sequence contains introns, or synthetic sequences having codons different than the native gene).

It is contemplated that pharmaceutical compositions may be prepared using the novel mutated viruses of the present invention. In such a case, the pharmaceutical composition comprises the novel virus of the present invention and a pharmaceutically acceptable carrier. A person having ordinary skill in this art readily would be able to determine, without undue

WO 99/13818

PCT/US98/19556

experimentation, the appropriate dosages and routes of administration of this viral vaccination compound. When used *in vivo* for therapy, the vaccine of the present invention is administered to the patient or an animal in therapeutically effective amounts, i.e., amounts that immunize the individual being treated from the disease associated with the particular virus. It will normally be administered parenterally, preferably intravenously, but other routes of administration will be used as appropriate. The amount of vaccine administered will typically be in the range of about 10^3 to about 10^6 pfu/kg of patient weight. The schedule will be continued to optimize effectiveness while balancing negative effects of treatment. See Remington's Pharmaceutical Science, 17th Ed. (1990) Mark Publishing Co., Easton, Penn.; and *Goodman and Gilman's: The Pharmacological Basis of Therapeutics* 8th Ed (1990) Pergamon Press; which are incorporated herein by reference. For parenteral administration, the vaccine will be most typically formulated in a unit dosage injectable form (solution, suspension, emulsion) in association with a pharmaceutically acceptable parenteral vehicle. Such vehicles are preferably non-toxic and non-therapeutic. Examples of such vehicles are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin.

The vaccines of the present invention are based on deletion mutations in the transmembrane domains of proteins of membrane-enveloped viruses. The strategy for production of these mutations is based on the following information: Unlike mammalian cell membranes, the membranes of insect cells contain no cholesterol (Clayton 1964, Mitsuhashi et al 1983). The presence of cholesterol in membranes in general makes the

WO 99/13818

PCT/US98/19556

membrane thicker, with the increase in thickness increasing as the amount of cholesterol increases (Bretscher, 1993). Many membrane-coated viruses have membrane glycoproteins on their surface which are responsible for identifying and infecting target
5 cells (Schlesinger, S. and M.J. Schlesinger, 1990). These membrane glycoproteins have hydrophobic membrane-spanning domains which anchor the proteins in the membrane bilayer (Rice et al 1982).

The membrane-spanning domains of these
10 transmembrane proteins must be long enough to reach from one side of the bilayer to the other in order to hold or anchor the proteins in the membrane. Experiments have shown that if the domains are shortened by the deletion of amino acids within the domain, the proteins do not appropriately associate with the
15 membrane and fall out (Adams and Rose. 1985).

Because insects have no cholesterol in their membranes, the insect-generated viral membrane will be thinner in cross section than the viral membranes generated from mammals. Since the membranes of insects are thinner, the
20 membrane-spanning domains of proteins integrated into insect membranes do not need to be as long as those integrated into the membranes of mammals. It is possible, therefore, to produce deletions in engineered viruses which remove amino acids from the transmembrane domain of the viral glycoprotein. This results
25 in a glycoprotein which can integrate normally into the membrane of a virus replication in an insect cell, but not into the membrane of a virus replicating in a mammal. Thus, the mutated virus is produced in the insect cell replicating as well as the parent, wildtype virus in the insect host. On the other hand, in mammals,

WO 99/13818

PCT/US98/19556

the mutant virus can infect the host producing viral proteins; however because the mutated virus glycoprotein cannot span and be anchored in the mammalian membrane, progeny virus cannot be produced in mammalian cells. An additional advantage to the approach of the present invention is that the mutants are engineered as deletion mutants, hence there is absolutely no chance for reversion to wildtype phenotype, a common problem with virus vaccines.

The vaccines envisioned by the present invention work for any membrane-enveloped viruses which grow in vertebrate and invertebrate cells. Indeed, the present invention is applicable to membrane-enveloped viruses which can be either engineered to grow in an insect cell, or to membrane-enveloped viruses which grow in genetically-modified insect cells.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion:

EXAMPLE 1

Site-Directed Mutagenesis of Toto 1101:

Using the full length clone of the Alpha virus Sindbis described previously (Liu et al 1996, Rice et al., 1987), a deletion removing 3 bases encoding a lysine at position 391 in the amino acid sequence of the virus glycoprotein E2 has been constructed. This lysine is part of the putative membrane-spanning domain of this protein (Rice et al 1982).

WO 99/13818

PCT/US98/19556

Site-directed mutagenesis was used to generate a deletion mutant (Lys391) in Toto 1101, a plasmid containing the full-length Sindbis cDNA and an SP6 promoter that can be used to transcribe infectious RNA from the clone *in vitro* (Rice et al., 1987
5 Liu and Brown, 1993a). Using the megaprimer method of PCR mutagenesis (Sarkar and Sommer, 1990) described previously (Liu and Brown, 1993a), three nucleotides were removed in the cDNA clone of Toto 1101, nucleotides (nts) 9801, 9802, 9803, resulting in the removal of the codon AAA (K391).

10 A 30 base oligonucleotide of the sequence, 5'CTCACGGCGCGCACAGGCACATAACACTGC3' (SEQ ID No.: 1) was used as the mutagenesis primer. This primer, along with the "forward primer" 5'CCATCAAGCAGTGCGTCG3' (SEQ ID No.: 2; 18mer), generated a 518 base "Megaprimer" (nucleotides 9295-
15 9813). The second PCR reaction consisted of 0.5 µg of megaprimer, 100 µg Toto 1101 template and 0.5 µg of the "reverse primer" 5' GGCAGTGTGCACCTTAATCGCCTGC 3' (SEQ ID No.: 3). All PCR reactions employed 30 cycles at 95 degrees for 1 min., 64 degrees for 1 min., 72 degrees for 1 min. and a final incubation at 72
20 degrees for 8 min. The resulting PCR product (1149 nts) was cleaved with BCL I and SPL and inserted into the corresponding site in Toto 1101, creating the deletion mutant K391. After the deletion was confirmed by dideoxynucleotide sequencing through the entire subcloned region using Sequenase™ (U. S. Biochemical,
25 Cleveland, OH), infectious RNA was transcribed *in vitro* using SP6 polymerase and was introduced (transfected) into BHK-21 cells.

EXAMPLE 2

In vitro transcription and RNA transfection

Plasmid DNA containing the full-length cDNA copy of Sindbis virus K391 or wild type RNA was linearized with XhoI and transcribed *in vitro* with SP6 RNA polymerase as described previously (Rice et. al., 1987). 1 µg of Xho I linearized K391 cDNA or wild type Sindbis virus cDNA was transcribed in buffer consisting of 80 mM Hepes pH 7.5, 12 mM MgCl, 10 mM DTT and 2 mM spermidine and 100 µgm BSA with 3 mM each ATP, UTP, CTP, 1.5 mM GTP and 4.5 mM m⁷ GpppG, 20 units SP6 RNA polymerase and 20 units RNase inhibitor in a 20 µl reaction volume. After incubation at 37°C for 2 hours, RNA production was assayed by running 2 µl of the RNA product on a 1% agarose gel.

Baby Hamster Kidney (BHK21) cells and *Aedes albopictus* (mosquito) cells were transfected with RNA derived from the mutant or wild type clone. Mosquito cell transfections were carried out using 5x10⁶ cells resuspended in electroporation buffer consisting of 20 mM Hepes pH 7.05, 137 mM NaCl, 0.7 mM Na₂HPO₄ and 6 mM dextran. Optimal electroporation parameters for these cells was found to be 2Kv 25µF, 1 resistance. Transfected cells were incubated at 37°C until cytopathic effect was observed (about 24 hours).

After 24 hours of incubation, the media was collected from both infected cell lines as well as non-RNA transfected controls. The media from each cell line was tested for the presence of infectious virus by plaque assay (Renz and Brown 1976) on mosquito and BHK-21 cell monolayers (Table 1).

TABLE I

Infectious virus produced by transfection of BHK21 or Aedes albopictus cells with Sindbis virus wild type or mutant K391

Cell line	BHK Mock Transfected	BHK Wild Type RNA	BHK with K391 RNA	AA Mock Transfected	AA Wild Type RNA	AA with K391 RNA
Media titered on BHK	no virus detected	5x10 ⁷ infectious virus/ml	no virus detected	no virus detected	2x10 ⁷ infectious virus/ml	no virus detected
Media titered on AA	no virus detected	8x10 ⁷ infectious virus/ml	no virus detected	no virus detected	4x10 ⁷ infectious virus/ml	1x10 ⁷ infectious virus/ml

a. Mock indicates that transfection protocol was carried out without RNA

As shown in Table 1, the mutant K391 produces infectious virus particles only when replicating in the insect cell. This virus, in turn, produced plaques only in mosquito cells. BHK
5 cells transfected with K391 produced no virus detectable when assays were done in either BHK or Aedes albopictus cells. If cultures of BHK were infected with the virus produced from the transfected mosquito cells, no detectable virus was produced. RNA encoding wild type virus produced infectious virus which, in
10 turn, produced plaques in both cell lines (Table 1).

EXAMPLE 3

15 Metabolic radioactive labeling of viral proteins:

Subconfluent monolayers of BHK21 cells in 25 cm² flasks were transfected with wild type or K391 mutant RNA as described above. Monolayers were starved for 30 min in methionine- and cysteine-free medium (MEM-E) containing 1%
20 FCS, 2 mM glutamine and 5% TPB (starvation medium). At 16 hours post-transfection, cells were pulse-labeled with starvation medium containing 50 µCi/ml [³⁵S] Met/Cys protein labeling mix for 20 minutes. Labeling was terminated by washing the monolayers with PBS containing 75 µg/ml cycloheximide.
25 Monolayers were chased for 45 minutes in medium containing 10 times the normal concentration of methionine and cysteine and 75 µg/ml cycloheximide.

EXAMPLE 4Immunoprecipitation and Polyacrylamide Gel Electrophoresis:

Radiolabeled viral proteins were immunoprecipitated
5 with antisera as described (Knipfer and Brown, 1989). [³⁵S]
Met/Cys labeled cells were washed twice in cold PBS and lysed in
lysis buffer: 0.5% NP-40, 0.02 M Tris HCl pH 7.4, 0.05 M NaCl, 0.2
mM PMSF, 0.2 mM TPCK and 0.02 mM TLCK. The nuclei were
10 pelleted by centrifugation and discarded. The supernatant was
pre-absorbed with 100 µl of protein A/Sepharose beads (Sigma)
suspended in lysis buffer for 1 hr, and the beads were pelleted.
The pre-absorbed supernatant was treated with 200 µl of protein
A/Sepharose beads coupled to rabbit anti-SVHR serum or E2 tail
monospecific polyclonal serum and agitated overnight at 4°C. The
15 immunoprecipitated bead-antibody-protein complexes were
washed three times with lysis buffer and then solubilized in SDS-
PAGE sample buffer consisting of 12% glycerol, 4% SDS, 50 mM
Tris pH 6.8, 5% mercaptoethanol and 0.02% bromphenol blue. The
samples were heated for 3 min at 95°C and the beads were
20 removed from the sample by centrifugation. Gel electrophoresis
was carried out on a 10.8% SDS-PAGE or 16% Tricine gel as
described previously (Liu and Brown, 1993 a,b). Fluorography
was performed as described (Bonner and Laskey, 1974) and dried
gels were exposed to Kodak XAR-5 film (see Figure 1).

25

EXAMPLE 5

Transmission Electron Microscopy

BHK-21 cell monolayers infected with K391 produced
5 from transfected mosquito cells or transfected with K391 RNA
were lifted from flasks by trypsin treatment at desired time
points, and the cells were pelleted by low speed centrifugation.
Cell pellets were washed twice in PBS and fixed in 4%
glutaraldehyde at 4°C overnight. The cells were then washed
10 three times with 0.2 M cacodylate buffer (pH 7.2), post-fixed with
2% osmium tetroxide for 1 hour at room temperature, and washed
three times in cacodylate buffer. The cells were stained en bloc
for 1 hr at room temperature with 0.5% uranyl acetate. After
three washes, cell pellets were embedded in 1% agarose and
15 dehydrated through a graded ethanol/acetone series. Final
embedding was in Mollenhauer's (1964) Epon-Araldite epoxy
mixture #1 at 70°C for two days. Ultrathin sections were cut on a
Sorvall MT5000 microtome and collected on 150 mesh copper
grids. Sections were stained with 1% uranyl acetate and/or lead
20 citrate and were photographed in a Jeol 100CX transmission
electron microscope (see Figure 2).

Although BHK cells infected with K391 virus or
transfected with K391 RNA produce no virus detectable by the
plaque assay, it was shown by PAGE that they do produce all virus
25 structural proteins (Figure 1). Further, it was shown by electron
microscopy that they assemble the intracellular (non infectious)
virus cores (Figure 2).

EXAMPLE 6Uses for the Sindbis deletion mutant K391 and similar mutations produced in other Togaviruses:

5 K391 produces Sindbis virus particles when allowed to replicate in mosquito cells. The exposed regions of the proteins (ecto domains) are wild type in sequence. These wild type proteins allow the virus to enter mammalian cells and produce virus proteins (see Figure 1) but new virus is not assembled as
10 shown by electron microscopy in Figure 2.

 K391 is a vaccine strain. It is produced in very high concentration in cultured insect cells. However, when the virus is injected into a mammalian host, the virus circulates and infects cells in a mammalian host, these infected cells produce and
15 present virus proteins for immune surveillance, but, because of the truncation in the membrane domain, the infection is limited to those cells infected initially by the inoculum. Because the vaccine strain is the result of a deletion mutation, reversion to wild type pathogenic phenotype is not possible.

20 Further, an engineered deletion mutant may be introduced into the wild mosquito population. It has been shown that these viruses are spread from the female parent to the progeny by a process of transovarial transmission (Leakey 1984). When these mosquitoes bite a vertebrate they will provide an
25 immunizing dose (10^6 infectious particles) of the vaccine strain (for example, K391). Karpf and Brown (1997) showed that infection of insect cells by one Alpha virus prevents the cells from being infected by another, even distantly-related alpha virus for an indefinite amount of time (over two years in cell culture, where

the life of a mosquito is 28 days). Thus, the presence of the vaccine strain (for example Sindbis K391) will block the spread of other related and pathogenic viruses by these insects.

5

EXAMPLE 7

Additional Deletion Mutations

Additional deletion mutations in the membrane spanning domain of Sindbis virus glycoprotein E2 were prepared.

10 The protocol for production of these deletion mutations described below. The procedure is described for the model membrane containing virus Sindbis, however, the procedure can be easily applied to any other virus membrane glycoprotein.

The envelope glycoproteins of Sindbis virus were

15 integrated into the membranes of the endoplasmic reticulum as a multi pass protein with 6 membrane spanning domains. There are, therefore, 6 potential targets for the production of deletion mutations which will prevent the correct integration of a transmembrane domain (See Fig. 3). Some of these targets are

20 less satisfactory for this procedure than others. TMD #1 (Fig. 2) is the signal sequence which is recognized by the Signal Recognition Particle and directs protein synthesis to the membranes of the ER. Truncating this domain would likely disturb targeting in both mammalian and insect cells. TMD #3 contains the protein

25 sequence of E2 which recognizes and binds capsid protein. It has been shown that this interaction is very specific in nature and requires the sequence that is in the transmembrane domain (Liu *et al.*, 1996; Lopez *et al.*, 1994). TMD#3, therefore, like TMD#1

WO 99/13818

PCT/US98/19556

has a functional as well as a structural component. A significant deletion in this domain would likely eliminate budding in both cell systems. This leaves four transmembrane domains which are targets for the production of deletions which will effect membrane
5 integration (Fig 3. TMD 2,4,5,6,).

The 6k protein is not a component of mature virus and its function in virus assembly is not clear. In the poly protein the proper integration and orientation of 6k in the ER membrane is essential for the correct integration of E1. The transmembrane
10 domains of 6k (TMD 4and5) are excellent targets for deletion mutation as failure to integrate one of these domains may cause the poly protein to integrate into the membrane in a wrong configuration or cause the failure to integrate E1. TMD 2 and 6 are the membrane spanning domains of E2 and E1 and are both
15 obvious targets for deletion mutation. Multiple membrane spanning domains in this poly protein suggest that if deletion mutations in a single transmembrane domain do not totally block virus production in mammalian cells, then deletions in additional membrane spanning domains can further reduce maturation to
20 negligible levels.

EXAMPLE 8Design of mutagenic primers for the E2 hydrophobic membrane anchor (TMD#2)

5 Protocols for testing the requirements placed on the transmembrane domain of E2 (Fig. 3, TMD 2) is given. This protocol can be easily replicated for any other of the Sindbis membrane spanning domains or the membrane spanning domains of any other virus glycoprotein. The hydrophobic Sindbis PE2 membrane anchor consists of 26 amino acids. As is common with
10 other membrane spanning domains little amino acid homology is conserved among the alphaviruses, although the length of this hydrophobic region is highly conserved (Strauss and Strauss, 1994). The lack of sequence conservation in this domain suggests that it is the hydrophobic properties of the
15 domain and not its sequence which is critical for integration.

 The transmembrane domain of E2 begins at amino acid 365 of the PE2 sequence. This hydrophobic region consists of the sequence: VYTLAVASATVAMMIGVTVAVLCAC (SEQ ID No.: 4). Adams and Rose (1985) demonstrated that a minimum of 14
20 amino acids in the transmembrane domain of the VSV G protein were necessary for proper anchoring in mammalian cells. Therefore, mutagenic primers have been designed which create a nested set of deletions in the E2 transmembrane domain. Beginning with a deletion of 16 amino acids (which leaves 10
25 amino acids in the hydrophobic region), a set of deletions were constructed which delete from as many as 16 amino acids, to as few as 1 amino acid from the membrane anchor (Figure 4).

Deletions were constructed using PCR megaprimer mutagenesis to generate deleted fragments containing unique BclI and SphI sites. All resulting constructs were installed into the wt Sindbis cDNA construct Toto Y420 to generate the mutant
5 plasmids. After linearization with XhoI and transcription using SP6 polymerase, transcripts were transfected into BHK or Aedes albopictus cells by electroporation (as described above). Production of infectious virus from these transfections were
10 titered on both BHK and C710 mosquito cells to determine the host range of these constructs. Table 2 shows the deleted sequences and the primer sequences used in their construction.

For each construct the same primer pair is used to generate the entire BclI to SphI region. The forward primer E1Bcl21 is comprised of the sequence from nucleotide 9306-9327
15 and reads from 5' -3' GCGTCGCCTATAAGAGCGACC (SEQ ID No.: 5). The reverse primer Sphext is comprised of the sequence from nucleotide 10420-10444 which is the complementary sequence reading from 5'-3' CAGTGTGCACCTTAATCGCCTGC (SEQ ID No.: 6).

The virus produced by transfection of insect cells is
20 tested for its ability to produce plaques in BHK and C7-10 mosquito cells as for the mutant E2 Δ K391. Those mutants which do not produce plaques in BHK cells are tested for their ability to infect BHK cell relative to wild type virus by immunofluorescence assay of infected monolayers. This later assay is compared to the
25 total protein in purified preparations of the mutant and wild type virus to establish the relative infectivity of each mutant population. The goal is to truncate the transmembrane domain as much as possible and still obtain reasonable amounts of virus in

WO 99/13818

PCT/US98/19556

C7-10 mosquito cell monolayers which can infect but not produce mature virus in BHK cells. If the circumstance arises that truncation of a single transmembrane domain reduces but does not eliminate virus growth in BHK cells a second domain will be
5 truncated and so fourth up to four domains.

WO 99/13818

PCT/US98/19556

TABLE 2Listing of the deletions in Sindbis E2 and the primers used

<u>PRIMER-DESIGNATED</u>	<u>NT. DELETED</u>	<u>SEQUENCE OF MUTAGENIC PRIMER</u>
E2TM10	9734-9782	ACATAACACTGCGATGGTGTACAC (SEQ ID No.: 7)
5		
E2 TM12	9740-9782	ACATAACACTGCGGCTAAGATGG (SEQ ID No.: 8)
E2 TM14	9746-9782	ACATAACACTGCTGCGACGGCT (SEQ ID No.: 9)
10		
E2 TM16	9743-9773	GCAACAGTTACGACGGCTAAG (SEQ ID No.: 10)
E2 TM17	9743-9770	ACAGTTACGCCGACGGCTAAG (SEQ ID No.: 11)
E2 TM18	9743-9767	GTTACGCCAATGACGGCTAAG (SEQ ID No.: 12)
15		
E2 TM19	9743-9764	CGCCAATCATGACGGCTAAGA (SEQ ID No.: 13)
E2 TM20	9755-9773	GCAACAGTTACGGTAGCTGA (SEQ ID No.: 14)
20		
E2 TM21	9755-9770	AGTTACGCCGGTAGCTGA (SEQ ID No.: 15)
E2 TM22	9761-9773	TGCAACAGTTACCGCCACGGT (SEQ ID No.: 16)
E2 TM23	9761-9770	ACAGTTACGCCCGCCACGGT (SEQ ID No.: 17)
25		
E2 TM24	9761-9767	GTTACGCCAATCGCCACGGT (SEQ ID No.: 18)
E2 TM25	9761-9764	ACGCCAATCATCGCCACGGT (SEQ ID No.: 19)

This protocol described by the present invention works for any virus which replicates in insects and mammals and has integral membrane proteins as part of its structure, namely, 5 Togaviruses, Flaviviruses and Bunya viruses and all other enveloped viruses which can replicate naturally in both mammalian and insect cells, as well as enveloped viruses which can be made to replicate in mammalian and insect cells by genetic engineering of either the virus or the cell.

10 Vaccines are made against any membrane-containing virus by removing amino acids from the membrane-spanning domain of a protein in the viral envelope. This is done by removing bases from a cDNA clone of the virus as described. RNA transcribed from the altered clone is transfected into insect cells. 15 The virus produced is amplified by repeated growth in insect cells until large quantities of mutant virus are obtained. This virus is tested for its ability to infect and produce progeny in mammalian cells. Virus which does not produce progeny in mammalian cells are tested for ability to produce immunity in laboratory animals. 20 Those which do produce immunity are candidates for production of human and animal vaccines as is known in the art. This protocol is employed with any arbovirus or other enveloped viruses.

The following references were cited herein:

25 Adams G.A. and Rose J.K. (1985) Structural requirements of a membrane-spanning domain for protein anchoring and cell surface transport. Cell. 41(3):1007-15

Berge, T.O. (ed.) (1975): *International Catalogue of Arboviruses*; 2nd ed., DHEW Publ. No. (CDC) 75-8301 (U.S. Government Office, Washington, D.C.)

Bonner, W. M., and R. A. Laskey. 1974. A film detection
5 method for tritium-labeled proteins and nucleic acids in polyacrylamide gels. Eur. J. Biochem. 46:83-88.

Bowers, D.F., B.A. Abell and D.T. Brown (1995). Replication and Tissue Tropism of the Alphavirus Sindbis in the Mosquito *Aedes Albopictus*. Virology 212: 1-12

10 Bretscher MS. (1993)Cholesterol and the Golgi apparatus. Science. 261(5126):1280-1

Brown, D.T., and L. Condreay (1986). Replication of alphaviruses in mosquito cells. In *The Togaviridae and Flaviviridae*. S. Schlesinger (ed.), pp. 473-501.

15 Clayton, R.B. 1964 The utilization of sterols by insects. J. lipid res. 5:3-19

Karpf, et al. (1997) J. Virol. 71:7119-7123.

Knipfer, M. E., and D. T. Brown. 1989. Intracellular transport and processing of Sindbis virus glycoproteins. Virology
20 170:117-122.

Leake, C.J. (1984). Transovarial transmission of arboviruses by mosquitoes. In *Vectors in Virus Biology* (Mayo and Harrap, eds.), pp. 63-92. Academic Press.

Liu, N., and D.T. Brown (1993a). Transient translocation of
25 the cytoplasmic (endo) domain of a type-I membrane glycoprotein into cellular membranes. J. Cell Biol. 120:877-883.

Liu, N., and D.T. Brown (1993b). Phosphorylation dephosphorylation events play critical roles in Sindbis virus maturation. J. Virol., 196:703-711.

- Liu N., H. Lee, R. Hernandez and D.T. Brown(1996) Mutations in the Endo Domain of Sindbis Glycoprotein E2 Block Phosphorylation, Reorientation of the Endo Domain and Nucleocapsid Binding. *Virology* 222: 236-246.
- 5 Mitsuhashi et al 1983. Sterol free eucaryotic cells from continuous cell lines of insects. *Cell Biol. Int. Rep.* 7:1057-1062.
- Mollenhauer, H. H. 1964. Plastic embedding mixture for use in electron microscopy. *Stain Techn.* 39:111-114.
- NIAID Report of the Task Force on Microbiology and
10 Infectious Diseases (1992). NIH Publication No. 92-3320.
- Renz, D., and D.T. Brown. 1976. Characteristics of Sindbis virus temperature-sensitive mutants in cultured BHK-21 and *Aedes albopictus* (mosquito) cells. *J. Virol.* 19:775-781.
- Rice C.M. et al 1982. Isolation and characterization of the
15 hydrophobic COOH-terminal domains of Sindbis virus glycoproteins. *J.Mol.Biol.* 154:355-378
- Rice., C.M., R. Levis, J.H. Strauss, and H.V. Huang. 1987. Production of infectious RNA transcripts from Sindbis virus cDNA clones: mapping of lethal mutations, rescue of a temperature-
20 sensitive marker, and in vitro mutagenesis to generate defined mutants. *J. Virol.* 61:3809-3819.
- Sarkar, G., and S. S. Sommer. 1990. The "megaprimer" method of site-directed mutagenesis. *BioTechniques.* 8:404-407.
- Schlesinger, S. and M.J. Schlesinger (1990). "Replication of
25 *Togaviridae* and *Flaviviridae*." (D.M. Knipe and B.N. Fields, eds.), In *Virology Vol. I*, pp. 697-711. Raven Press, Ltd., New York.
- Sprenger, D. and T. Wuithiranyagool (1985). The discovery and distribution of *Aedes albopictus* in Harris County, Texas. *J. Am. Mosquito Control Assoc.* 2:217-219

WO 99/13818

PCT/US98/19556

Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. Further, these patents and publications are incorporated by reference herein to the same
5 extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

One skilled in the art will appreciate readily that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those
10 objects, ends and advantages inherent herein. The present examples, along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes
15 therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.

WO 99/13818

1 / 13

PCT/US98/19556

SEQUENCE LISTING

<110> Brown, Dennis T.
Hernandez, Raquel

<120> Production of Vaccines Using Arthropod
Vectored Viruses

<130> D6123

<140>

<141> 1998-09-18

<150> US 60/059,668

<151> 1997-09-18

<160> 34

<210> 1

<211> 30

<212> DNA

<213> artificial sequence

<220>

<223> Used as the mutagenesis primer with the "forward
primer" to generate a 518 base "Megaprimer"
corresponding to nucleotides 9295-9813.

<400> 1

ctcacggcgc gcacagggcac ataacactgc 30

<210> 2

<211> 18

<212> DNA

<213> artificial sequence

<220>

<223> Used as the "forward primer" with the mutagenesis
primer to generate a 518 base megaprimer
corresponding to nucleotides 9295-9813.

<400> 2

ccatcaagca gtgcgtcg 18

<210> 3

<211> 25

<212> DNA

<213> artificial sequence

WO 99/13818

2 / 13

PCT/US98/19556

<220>

<223>

Used as the "reverse primer" with the megaprimer and the Toto 1101 plasmid template to create 1149 nucleotide product used to create the deletion mutant K391 in Toto 1101.

<400>

3

ggcagtggtgc accttaatcg cctgc

25

<210>

4

<211>

26

<212>

PRT

<213>

Sindbis virus

<220>

<222>

365..390

<400>

4

Val Tyr Thr Ile Leu Ala Val Ala Ser Ala Thr Val Ala Met Met

5

10

15

Ile Gly Val Thr Val Ala Val Leu Cys Ala Cys

20

25

<210>

5

<211>

21

<212>

DNA

<213>

artificial sequence

<220>

<222>

9306-9327

<223>

Forward primer ElBcl21 from megaprimer used with reverse primer to generate deletion constructs containing unique BclI and SplI sites.

<400>

5

gcgtcgccta taagagcgac c

21

<210>

6

<211>

21

WO 99/13818

3 / 13

PCT/US98/19556

<212> DNA
 <213> artificial sequence
 <220>
 <222> 10420-10444
 <223> Reverse primer Splext from megaprimer used with forward primer to generate deletion constructs containing unique BclI and SplI sites.
 <400> 6

<210> 7
 <211> 24
 <212> DNA
 <213> artificial sequence
 <220>
 <223> Mutagenic primer (negative strand) used to create a deletion in the E2 transmembranal domain in the Sindbis viral glycoprotein.
 <400> 7

acataacact gcgatggtgt acac 24

<210> 8
 <211> 23
 <212> DNA
 <213> artificial sequence
 <220>
 <223> Mutagenic primer (negative strand) used to create a deletion in the E2 transmembranal domain in the Sindbis viral glycoprotein.
 <400> 8

acataacact gcggctaaga tgg 23

<210> 9
 <211> 22
 <212> DNA
 <213> artificial sequence

WO 99/13818

4 / 13

PCT/US98/19556

<220>

<223> Mutagenic primer (negative strand) used to create a deletion in the E2 transmembranal domain in the Sindbis viral glycoprotein.

<400> 9

acataacact gctgcgacgg ct 22

<210> 10

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> Mutagenic primer (negative strand) used to create a deletion in the E2 transmembranal domain in the Sindbis viral glycoprotein.

<400> 10

gcaacagtta cgacggctaa g 21

<210> 11

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> Mutagenic primer (negative strand) used to create a deletion in the E2 transmembranal domain in the Sindbis viral glycoprotein.

<400> 11

acagttacgc cgacggctaa g 21

<210> 12

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> Mutagenic primer (negative strand) used to create

WO 99/13818

5 / 13

PCT/US98/19556

a deletion in the E2 transmembranal domain in
the Sindbis viral glycoprotein.

<400> 12

gttacgccaa tgacggctaa g 21

<210> 13

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> Mutagenic primer (negative strand) used to create
a deletion in the E2 transmembranal domain in
the Sindbis viral glycoprotein.

<400> 13

cgccaatcat gacggctaag a 21

<210> 14

<211> 20

<212> DNA

<213> artificial sequence

<220>

<223> Mutagenic primer (negative strand) used to create
a deletion in the E2 transmembranal domain in
the Sindbis viral glycoprotein.

<400> 14

gcaacagtta cggtagctga 20

<210> 15

<211> 18

<212> DNA

<213> artificial sequence

<220>

<223> Mutagenic primer (negative strand) used to create
a deletion in the E2 transmembranal domain in
the Sindbis viral glycoprotein.

WO 99/13818

6 / 13

PCT/US98/19556

<400> 15

agttacgccg gtagctga

18

<210> 16

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> Mutagenic primer (negative strand) used to create
a deletion in the E2 transmembranal domain in
the Sindbis viral glycoprotein.

<400> 16

tgcaacagtt accgccacgg t

21

<210> 17

<211> 20

<212> DNA

<213> artificial sequence

<220>

<223> Mutagenic primer (negative strand) used to create
a deletion in the E2 transmembranal domain in
the Sindbis viral glycoprotein.

<400> 17

acagttacgc ccgccacggt

20

<210> 18

<211> 20

<212> DNA

<213> artificial sequence

<220>

<223> Mutagenic primer (negative strand) used to create
a deletion in the E2 transmembranal domain in
the Sindbis viral glycoprotein.

<400> 18

WO 99/13818

7 / 13

PCT/US98/19556

gttacgccaa tcgccacggt

20

<210> 19

<211> 20

<212> DNA

<213> artificial sequence

<220>

<223> Mutagenic primer (negative strand) used to create
a deletion in the E2 transmembranal domain in
the Sindbis viral glycoprotein.

<400> 19

acgccaatca tcgccacggt

20

<210> 20

<211> 849870

<212> DNA

<213> Sindbis virus

<220>

<223>

<400> 20

catcctgtgt acaccatctt agccgtcgca tcagctaccg tggcgatgat gattggcgta 60

actgttgcag tggtatgtgc ctgt

84

<210> 21

<211> 28

<212> PRT

<213> Sindbis virus

<220>

<222> 363..390

<400> 21

His Pro Val Tyr Thr Ile Leu Ala Val Ala Ser Ala Thr Val Ala

5

10

15

WO 99/13818

8 / 13

PCT/US98/19556

Met Met Ile Gly Val Thr Val Ala Val Leu Cys Ala Cys

20

25

<210> 22

<211> 27

<212> PRT

<213> artificial sequence

<220>

<223> Sequence of the E2 transmembranal domain
of the Sindbis viral glycoprotein after deleting
amino acid 378.

<400> 22

His Pro Val Tyr Thr Ile Leu Ala Val Ala Ser Ala Thr Val Ala

5

10

15

Met Ile Gly Val Thr Val Ala Val Leu Cys Ala Cys

20

25

<210> 23

<211> 26

<212> PRT

<213> artificial sequence

<220>

<223> Sequence of the E2 transmembranal domain
of the Sindbis viral glycoprotein after deleting
amino acids 378 and 379.

<400> 23

His Pro Val Tyr Thr Ile Leu Ala Val Ala Ser Ala Thr Val Ala

5

10

15

Ile Gly Val Thr Val Ala Val Leu Cys Ala Cys

20

25

<210> 24

WO 99/13818

9 / 13

PCT/US98/19556

<211> 25
 <212> PRT
 <213> artificial sequence
 <220>
 <223> Sequence of the E2 transmembranal domain
 of the Sindbis viral glycoprotein after deleting
 amino acids 378 through 380.

<400> 24

His Pro Val Tyr Thr Ile Leu Ala Val Ala Ser Ala Thr Val Ala

5 10 15

Gly Val Thr Val Ala Val Leu Cys Ala Cys

20 25

<210> 25
 <211> 24
 <212> PRT
 <213> artificial sequence
 <220>
 <223> Sequence of the E2 transmembranal domain
 of the Sindbis viral glycoprotein after deleting
 amino acids 378 through 381.

<400> 25

His Pro Val Tyr Thr Ile Leu Ala Val Ala Ser Ala Thr Val Ala

5 10 15

Val Thr Val Ala Val Leu Cys Ala Cys

20

<210> 26
 <211> 23
 <212> PRT
 <213> artificial sequence
 <220>
 <223> Sequence of the E2 transmembranal domain

WO 99/13818

10 / 13

PCT/US98/19556

of the Sindbis viral glycoprotein after deleting
amino acids 376 through 380.

<400> 26

His Pro Val Tyr Thr Ile Leu Ala Val Ala Ser Ala Thr Gly Val
5 10 15

Thr Val Ala Val Leu Cys Ala Cys
20

<210> 27

<211> 22

<212> PRT

<213> artificial sequence

<220>

<223> Sequence of the E2 transmembranal domain
of the Sindbis viral glycoprotein after deleting
amino acids 376 through 381.

<400> 27

His Pro Val Tyr Thr Ile Leu Ala Val Ala Ser Ala Thr Val Thr
5 10 15

Val Ala Val Leu Cys Ala Cys
20

<210> 28

<211> 21

<212> PRT

<213> artificial sequence

<220>

<223> Sequence of the E2 transmembranal domain
of the Sindbis viral glycoprotein after deleting
amino acids 372 through 378.

<400> 28

WO 99/13818

11 / 13

PCT/US98/19556

His Pro Val Tyr Thr Ile Leu Ala Val Met Ile Gly Val Thr Val

5

10

15

Ala Val Leu Cys Ala Cys

20

<210> 29

<211> 20

<212> PRT

<213> artificial sequence

<220>

<223> Sequence of the E2 transmembranal domain
of the Sindbis viral glycoprotein after deleting
amino acids 372 through 379.

<400> 29

His Pro Val Tyr Thr Ile Leu Ala Val Ile Gly Val Thr Val Ala

5

10

15

Val Leu Cys Ala Cys

20

<210> 30

<211> 19

<212> PRT

<213> artificial sequence

<220>

<223> Sequence of the E2 transmembranal domain
of the Sindbis viral glycoprotein after deleting
amino acids 372 through 380.

<400> 30

His Pro Val Tyr Thr Ile Leu Ala Val Gly Val Thr Val Ala Val

5

10

15

Leu Cys Ala Cys

WO 99/13818

12 / 13

PCT/US98/19556

<210> 31
 <211> 18
 <212> PRT
 <213> artificial sequence
 <220>
 <223> Sequence of the E2 transmembranal domain
 of the Sindbis viral glycoprotein after deleting
 amino acids 372 through 381.

<400> 31

His Pro Val Tyr Thr Ile Leu Ala Val Val Thr Val Ala Val Leu

5

10

15

Cys Ala Cys

<210> 32
 <211> 16
 <212> PRT
 <213> artificial sequence
 <220>
 <223> Sequence of the E2 transmembranal domain
 of the Sindbis viral glycoprotein after deleting
 amino acids 373 through 384.

<400> 32

His Pro Val Tyr Thr Ile Leu Ala Val Ala Ala Val Leu Cys Ala

5

10

15

Cys

<210> 33
 <211> 14
 <212> PRT
 <213> artificial sequence
 <220>
 <223> Sequence of the E2 transmembranal domain
 of the Sindbis viral glycoprotein after deleting
 amino acids 371 through 384.

WO 99/13818

13 / 13

PCT/US98/19556

<400> 33

His Pro Val Tyr Thr Ile Leu Ala Ala Val Leu Cys Ala Cys

5

10

<210> 34

<211> 12

<212> PRT

<213> artificial sequence

<220>

<223> Sequence of the E2 transmembranal domain
of the Sindbis viral glycoprotein after deleting
amino acids 369 through 384.

<400> 34

His Pro Val Tyr Thr Ile Ala Val Leu Cys Ala Cys

5

10

WHAT IS CLAIMED IS:

1. A genetically-engineered, membrane-enveloped virus, wherein said virus codes for a transmembrane protein having a deletion of one or more amino acids, and wherein said deletion provides a transmembrane protein that is able to span said membrane resulting in cells which produce infectious virus particles when said engineered virus replicates in insect cells, but that is unable to span said membrane resulting in cells which produce non-infectious virus particles when said virus replicates in mammalian cells.

2. The genetically-engineered, membrane-enveloped virus of claim 1, wherein said virus is capable of growth in insect and mammalian cells and is an Arthropod vectored virus.

3. The virus of claim 1, wherein said virus is selected from the group of Togaviruses, Flaviviruses, Bunya viruses, enveloped viruses capable of replication naturally in mammalian and insect cells, and enveloped viruses which replicate in mammalian and insect cells as a result of genetic engineering of either the virus or the cell.

4. The genetically-engineered, membrane-enveloped virus of claim 1, wherein said insect cells are mosquito cells.

WO 99/13818

PCT/US98/19556

5. The mosquito cells of claim 4, wherein said mosquito cells are *Aedes albopictus* cells.

6. The genetically-engineered, membrane-
5 enveloped virus of claim 1, wherein said virus is Sindbis Virus, said transmembrane protein is viral glycoprotein E2 and said mammal is a human.

7. The genetically-engineered, membrane-
10 enveloped virus of claim 1, wherein said virus is K391 virus.

8. The genetically-engineered, membrane-
enveloped virus of claim 1, wherein said transmembrane protein is
15 selected from the group of glycoprotein E1, glycoprotein E2, and G protein; and wherein said virus is selected from the group of HSV, HIV, rabies virus, Hepatitis, and Respiratory Syncycial Virus.

9. The genetically-engineered, membrane-
20 enveloped virus of claim 1, wherein said transmembrane protein is Env and said viruses are RNA tumor viruses.

10. A method of producing a viral vaccine from a
25 genetically-engineered, membrane-bound virus for vaccination of mammals, comprising the steps of:

WO 99/13818

PCT/US98/19556

engineering an amino acid deletion in a viral transmembrane protein to produce an engineered virus, wherein said transmembrane protein is able to span said membrane envelope when said engineered virus replicates in insect cells, but
5 is unable to span said membrane envelope when said virus replicates in mammalian cells, and wherein said virus remains capable of replicating in insect cells;

introducing said mutated virus into insect cells; and
allowing said mutated virus to replicate in said insect
10 cells to produce a viral vaccine.

11. The method of claim 10, wherein said genetically-engineered, membrane-enveloped virus is capable of growth in
15 insect and mammalian cells and is an Arthropod vectored virus or any virus capable of replicating, etc..

20 12. The method of claim 10, wherein said virus is selected from the group of Togaviruses, Flaviviruses, Bunya viruses, enveloped viruses capable of replication naturally in both mammalian and insect cells, and other enveloped viruses which can be made to replicate in mammalian and insect cells by genetic
25 engineering of either the virus or the cell.

WO 99/13818

PCT/US98/19556

13. A method for vaccination of an individual comprising the steps of:

introducing said viral vaccine of claim 10 into mammalian cells; and

5 allowing said viral vaccine to produce viral proteins for immune surveillance in said mammal and to stimulate immune system for antibody production.

10 14. A method of producing a viral vaccine to diseases spread by a mosquito population, comprising the steps of:

genetically engineering an amino acid deletion in a viral transmembrane protein to produce an engineered virus, wherein said transmembrane protein is able to span the membrane
15 envelope when said engineered virus replicates in mosquito cells, but is unable to span said membrane envelope when said virus replicates in mammalian cells, and wherein said virus remains capable of replicating in mosquito cells;

introducing the mutated virus into the wild mosquito
20 population; and

allowing the mutated virus to replicate in cells of the wild mosquito population to produce a population of mosquitos which harbor the vaccine strain of the virus and exclude the wild type (pathogenic) virus such that the mosquito bite delivers the
25 vaccine to a mammal.

WO 99/13818

PCT/US98/19556

1 2 3



FIG. 1

WO 99/13818

2 / 5

PCT/US98/19556



FIG. 2A

WO 99/13818

3 7 5

PCT/US98/19556



FIG. 2B




FIGURE 3

W
C
S
O
I